清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

医学 雄激素剥夺疗法 前列腺癌 安慰剂 临床终点 内科学 前列腺特异性抗原 随机对照试验 肿瘤科 泌尿科 癌症 病理 替代医学
作者
Fred Saad C,David F Cella,Ethan Basch,Boris Alexander Hadaschik,Paul N. Mainwaring,Stéphane Marie. Oudard,Julie Nicole Graff,Kelly McQuarrie,Susan Li,Stacie A. Hudgens,Joe Lawson,Angela Mennicke Lopez- Gitlitz,Margaret K. Yu,Matthew Raymond Smith,Eric Jay Small
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (10): 1404-1416 被引量:132
标识
DOI:10.1016/s1470-2045(18)30456-x
摘要

Summary Background In the SPARTAN trial, addition of apalutamide to androgen deprivation therapy, as compared with placebo plus androgen deprivation therapy, significantly improved metastasis-free survival in men with non-metastatic castration-resistant prostate cancer who were at high risk for development of metastases. We aimed to investigate the effects of apalutamide versus placebo added to androgen deprivation therapy on health-related quality of life (HRQOL). Methods SPARTAN is a multicentre, international, randomised, phase 3 trial. Participants were aged 18 years or older, with non-metastatic castration-resistant prostate cancer, a prostate-specific antigen doubling time of 10 months or less, and a prostate-specific antigen concentration of 2 ng/mL or more in serum. Patients were randomly assigned (2:1) to 240 mg oral apalutamide per day plus androgen deprivation therapy, or matched oral placebo plus androgen deprivation therapy, using an interactive voice randomisation system. Permuted block randomisation was used according to the three baseline stratification factors: prostate-specific antigen doubling time (>6 months vs ≤6 months), use of bone-sparing drugs (yes vs no), and presence of local-regional nodal disease (N0 vs N1). Each treatment cycle was 28 days. The primary endpoint was metastasis-free survival. The trial was unblinded in July, 2017. In this prespecified exploratory analysis we assessed HRQOL using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EQ-5D-3L questionnaires, which we collected at baseline, day 1 of cycle 1 (before dose), day 1 of treatment cycles 1–6, day 1 of every two cycles from cycles 7 to 13, and day 1 of every four cycles thereafter. This study is registered with ClinicalTrials.gov, number NCT01946204. Findings Between Oct 14, 2013, and Dec 15, 2016, we randomly assigned 1207 patients to receive apalutamide (n=806) or placebo (n=401). The clinical cutoff date, as for the primary analysis, was May 19, 2017. Median follow-up for overall survival was 20·3 months (IQR 14·8–26·6). FACT-P total and subscale scores were associated with a preservation of HRQOL from baseline to cycle 29 in the apalutamide group; there were similar results for EQ-5D-3L. At baseline, the mean for FACT-P total score in both the apalutamide and placebo groups were consistent with the FACT-P general population norm for US adult men. Group mean patient-reported outcome scores over time show that HRQOL was maintained from baseline after initiation of apalutamide treatment and was similar over time among patients receiving apalutamide versus placebo. Least-squares mean change from baseline shows that HRQOL deterioration was more apparent in the placebo group. Interpretation In asymptomatic men with high-risk non-metastatic castration-resistant prostate cancer, HRQOL was maintained after initiation of apalutamide treatment. Considered with findings from SPARTAN, patients who received apalutamide had longer metastasis-free survival and longer time to symptomatic progression than did those who received placebo, while preserving HRQOL. Funding Janssen Research & Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wyl完成签到 ,获得积分10
刚刚
莫忘初心完成签到,获得积分10
1秒前
kaka完成签到,获得积分10
1秒前
129完成签到,获得积分10
1秒前
如歌完成签到,获得积分10
3秒前
205完成签到,获得积分10
6秒前
卡卡完成签到,获得积分10
6秒前
聪明的羿完成签到,获得积分10
6秒前
6秒前
顺心凝阳完成签到,获得积分10
7秒前
shiluodeqiou完成签到,获得积分10
8秒前
白昼完成签到,获得积分10
9秒前
ZHZ完成签到,获得积分10
9秒前
321987杰完成签到 ,获得积分10
11秒前
内向的镜子完成签到,获得积分10
11秒前
MaidLingYan完成签到,获得积分10
11秒前
huan完成签到,获得积分10
14秒前
ssnwlp123完成签到,获得积分10
14秒前
BlueLe完成签到,获得积分10
15秒前
Zilaap完成签到,获得积分10
16秒前
CaptainMus完成签到,获得积分10
17秒前
端庄的如松完成签到,获得积分10
17秒前
皮卡皮卡皮卡丘完成签到,获得积分10
18秒前
Maestro_S的应助被科研通管家采纳,获得10
19秒前
null的应助被科研通管家采纳,获得10
20秒前
花开富贵完成签到,获得积分10
21秒前
luyu完成签到,获得积分10
21秒前
mayberichard完成签到,获得积分10
21秒前
热情善斓完成签到,获得积分10
22秒前
dianeil发布了新的文献求助10
22秒前
hh完成签到,获得积分10
24秒前
昊儿虫完成签到,获得积分10
24秒前
宝哥完成签到,获得积分10
24秒前
顺心雁开完成签到,获得积分10
27秒前
Cling5899完成签到,获得积分10
28秒前
bao完成签到,获得积分10
29秒前
小冯完成签到,获得积分10
33秒前
fomo完成签到,获得积分0
34秒前
坦率钢笔完成签到,获得积分10
35秒前
yuan完成签到,获得积分10
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280